Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Silodosin vs tamsulosin, with or without Ningmitai, for BPH with LUTS
ChiCTR2200061362Phase 4Not yet recruiting
- Sponsor
- Beijing Tongren Hospital
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in benign prostatic hyperplasia (BPH) and Micturition disorder comparing Tamsulosin + Ningmitai placebo, Silodosin + Ningmitai placebo and Silodosin + Ningmitai (3 arms). Primary endpoint: International Prostate Symptom Score. Planned start Dec 2021; status: not yet recruiting.
02
Drugs
silodosin
03
Conditions
benign prostatic hyperplasia (BPH)Micturition disorder
Beyond the preview
Go deeper on ChiCTR2200061362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200061362.